Syndicated Research Studies

Global Nuclear Medicine Market Overview The global nuclear medicine market was valued at USD 17.77 billion in 2024 and is expected to grow to USD 34.51 billion by 2030, expanding at a compound annual growth rate (CAGR) of 10.16% from 2025 to 2030. The market’s growth is driven by a strong pipeline of products under development and supportive government initiatives aimed at improving access to nuclear medicine. Currently, several promising products such as betalutin, omburtamab, yttrium-90 microspheres, PNT2003, and 177Lu PNT2002 are in various stages of clinical trials. The industry faced moderate disruptions during the COVID-19 pandemic; however, nuclear reactors were generally classified as essential services due to their critical nature and thus remained operational. For example, South Africa’s SAFARI-1 reactor continued operations throughout the lockdown, as stipulated by Section 71 of the Labour Act 66 of 1995. Market Drivers and Industry Context According to the W...

Nuclear Medicine Industry Overview The global  nuclear medicine market  size is expected to reach USD 24.4 billion by 2030, expanding at a CAGR of 13.0% from 2022 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of chronic diseases such as cancer & thyroid is anticipated to drive market growth. The impending approval of multiple radiopharmaceutical therapeutics during the forecast period will be a major driver for the market. For instance, in March 2022, Novartis AG received approval for Pluvicto (Lu 177) for the treatment of adult patients with prostate cancer . Nuclear Medicine Market Segmentation Grand View Research has segmented the global nuclear medicine market based on product type, application, and region: Based on the Product Type Insights, the market is segmented into Diagnostic products and Therapeutic Products. The diagnostic product segment held the highest market share in 2021 owing to the presence of a large p...